Celltech Group (NYSE: CLL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celltech Group (NYSE: CLL)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tom Nealon who started this subject	1/5/2004 3:47:12 PM
From: nigel bates	of 123

ZURICH, Jan 5 (Reuters) - Swiss drug firm Actelion (Zurich:ATLN.S - News) said on Monday its Zavesca capsules for the treatment of a rare genetic disorder were available in the United States. The firm said Zavesca was the first oral treatment for type 1 Gaucher disease, which affects an estimated 10,000 people worldwide. The only other U.S.-approved treatment is infusion-delivered enzyme replacement therapy. Actelion licenses Zavesca from Celltech Group (London:CCH.L - News). The two firms are conducting clinical studies on Zavesca for treatment of disorders such as type 3 Gaucher disease, Niemann-Pick type C, and late-onset Tay-Sachs...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next